Publication details
Edoxaban - další z nových perorálních antikoagulancií
| Title in English | Edoxaban - another of the new oral anticoagulants |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapeutická revue |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | anticoagulation; atrial fibrillation; cardioversion; tromboembolic disease |
| Description | Blockade of factor Xa becomes a routine part of clinical praxis instead of coumarine blockade with warfarin, providing a more benfitial and safer effect. The main indiactions are nonvalvular atrial fibrillation, deep venous trombosis, lung embolism and in recent time also electric cardioversion. Edoxaban appears as the fourth drug which has also evidence based data from clinical trials. Its advantage is also a once daily dosage. |